A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Active:	No
Cancer Type:	Head and Neck Cancer	NCT ID:	NCT03752398
Trial Phases:	Phase I	Protocol IDs:	XmAb23104-01 (primary) NCI-2019-00828 DUET-3
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Xencor, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03752398

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and
regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity,
and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination
therapy with ipilimumab in subjects with selected advanced solid tumors.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.